Artelo Biosciences, INC DEF 14A proxy statements

Artelo Biosciences schedules its 2026 Annual Meeting for July 17, 2026, to elect directors and seek approval to triple authorized common stock.

Artelo Biosciences, Inc. has supplemented its proxy statement to include a new proposal for stockholder approval: the ratification of MaloneBailey LLP as its independent auditor for the fiscal year ending December 31, 2026, at its adjourned virtual Annual Meeting on January 30, 2026.

Artelo Biosciences announces its 2025 Annual Meeting to elect directors and vote on executive compensation, following a year of continued net losses and declining shareholder returns.

Artelo Biosciences, Inc. calls a special stockholder meeting to approve a significant increase in authorized common and preferred stock to address Nasdaq non-compliance and facilitate future capital raises.

Artelo Biosciences, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

Artelo Biosciences will hold its 2024 Annual Meeting of Stockholders virtually on December 20, 2024, to elect directors and ratify the appointment of its independent accounting firm.